{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CG Oncology, Inc.
Is CG Oncology, Inc. overvalued or undervalued?
As of May 13, 2025, CG Oncology, Inc. is classified as overvalued with a valuation grade of "does not qualify" due to extremely negative financial ratios and poor operational performance, including a Return on Capital Employed of -691.63% and a year-to-date return of -10.53%.
Is CG Oncology, Inc. technically bullish or bearish?
As of June 20, 2025, the market trend is neutral with mixed signals, indicating a consolidation phase rather than a clear bullish or bearish direction.
What does CG Oncology, Inc. do?
CG Oncology, Inc. is a small-cap company in the miscellaneous industry, reporting net sales of $0 million and a net loss of $34 million as of March 2025. It has a market cap of approximately $2 billion and does not pay dividends.
How big is CG Oncology, Inc.?
As of Jun 18, CG Oncology, Inc. has a market capitalization of $2,000.15 million, with net sales of $0.66 million and a net profit of -$105.56 million over the latest four quarters. The company reported shareholder's funds of $733.38 million and total assets of $754.80 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
